Accessibility Menu
 
Entrada Therapeutics logo

Entrada Therapeutics

(NASDAQ) TRDA

Current Price$11.79
Market Cap$450.61M
Since IPO (2021)-51%
5 YearN/A
1 Year+23%
1 Month-1%

Entrada Therapeutics Financials at a Glance

Market Cap

$450.61M

Revenue (TTM)

$25.42M

Net Income (TTM)

$143.75M

EPS (TTM)

$-3.47

P/E Ratio

-3.39

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.79

Volume

1

Open

$11.90

Previous Close

$11.77

Daily Range

$11.50 - $12.35

52-Week Range

$4.93 - $13.65

TRDA News

TRDA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Entrada Therapeutics

Industry

Biotechnology

Employees

152

CEO

Dipal Doshi, MBA

Headquarters

Boston, MA 02210, US

TRDA Financials

Key Financial Metrics (TTM)

Gross Margin

-54%

Operating Margin

-6%

Net Income Margin

-6%

Return on Equity

-39%

Return on Capital

-45%

Return on Assets

-38%

Earnings Yield

-29.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$450.61M

Shares Outstanding

38.28M

Volume

1

Short Interest

0.00%

Avg. Volume

225.08K

Financials (TTM)

Gross Profit

$21.32M

Operating Income

$156.00M

EBITDA

$142.40M

Operating Cash Flow

$128.51M

Capital Expenditure

$1.04M

Free Cash Flow

$129.55M

Cash & ST Invst.

$295.70M

Total Debt

$50.93M

Entrada Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.30M

-96.5%

Gross Profit

$413.00K

-98.9%

Gross Margin

31.79%

N/A

Market Cap

$450.61M

N/A

Market Cap/Employee

$2.46M

N/A

Employees

183

N/A

Net Income

$39.16M

-3562.8%

EBITDA

$41.86M

-758.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$244.77M

-32.2%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$46.79M

-9.4%

Short Term Debt

$4.14M

-45.3%

Return on Assets

-38.09%

N/A

Return on Invested Capital

-44.74%

N/A

Free Cash Flow

$32.00M

+0.8%

Operating Cash Flow

$32.20M

-1.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVIRAtea Pharmaceuticals, Inc.
$5.08-0.78%
VNDAVanda Pharmaceuticals Inc.
$6.65-3.76%
ALLOAllogene Therapeutics, Inc.
$2.22-1.77%
VYGRVoyager Therapeutics, Inc.
$3.87-2.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$37.89-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.13-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$89.42+0.02%
IBITiShares Bitcoin Trust
$37.68+0.01%

Questions About TRDA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.